(Q39634078)

13 September 2017

1 reference

title

Systemic scleroderma. Clinical and pathophysiologic aspects (English)

1 reference

13 September 2017

1 reference

Krieg T

1

1 reference

PubMed ID

3280619

13 September 2017

Meurer M

series ordinal

2

1 reference

PubMed ID

3280619

13 September 2017

language of work or name

English

0 references

publication date

1 March 1988

1 reference

Journal of the American Academy of Dermatology

13 September 2017

1 reference

13 September 2017

18

1 reference

13 September 2017

3

1 reference

13 September 2017

457-481

1 reference

The visceral manifestations of scleroderma

13 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

An Historical Account of the Study of Progressive Systemic Sclerosis (Diffuse Scleroderma)

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Systemic scleroderma, A clinical study of 727 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Epidemiology of Systemic Sclerosis (Scleroderma)

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Increased frequency of HLA-DR5 in scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

HLA antigens, autoantibodies and clinical subsets in scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

DR antigens in systemic sclerosis: lack of clinical correlations

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Histocompatibility antigens in progressive systemic sclerosis (PSS; scleroderma)

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Preliminary criteria for the classification of systemic sclerosis (scleroderma)

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Scleroderma and the Subcutaneous Tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Immunofluorescence analysis of collagen, fibronectin, and basement membrane protein in scleroderma skin

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Collagen Fibrils of the Scleroderma in Ultra-thin Skin Sections

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Manometric assessment of oesophageal involvement in progressive systemic sclerosis, morphoea and Raynaud's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Early changes in oesophageal function in progressive systemic sclerosis: a comparison of manometry and radiology

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Barrett's esophagus complicating scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Comparative esophageal and anorectal motility in scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Steatorrhoea in Progressive Systemic Sclerosis (Scleroderma)

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Small intestinal bacterial growth in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Gastrointestinal telangietasia as a cause of severe blood loss in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

CHRONIC DISEASE OF THE LIVER ASSOCIATED WITH SYSTEMIC SCLERODERMA

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Rheumatic disorders in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Anticentromere antibodies in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Primary heart disease in systemic sclerosis (scleroderma): advances in clinical and pathologic features, pathogenesis, and new therapeutic approaches

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

The heart in scleroderma: noninvasive assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

The relationship arrhythmias and conduction disturbances to other manifestations of cardiopulmonary disease in progressive systemic sclerosis (PSS).

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Decreased coronary reserve in primary scleroderma myocardial disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

The electrocardiogram in systemic sclerosis (scleroderma). Study of 102 consecutive cases with functional correlations and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Pulmonary insufficiency; a study of 122 cases of chronic pulmonary emphysema

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Lung Involvement in Scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Evidence for chronic inflammation as a component of the interstitial lung disease associated with progressive systemic sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Small airways in progressive systemic sclerosis (PSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Pulmonary involvement in systemic sclerosis (scleroderma)

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Renal involvement in progressive systemic sclerosis (generalized scleroderma)

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

The kidney in progressive systemic sclerosis: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

The Nature of Joint Involvement in Progressive Systemic Sclerosis (Diffuse Scleroderma)

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

The articular manifestations of progressive systemic sclerosis (scleroderma).

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

The joint manifestations of the connective tissue diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Skeletal muscle involvement in progressive systemic sclerosis (scleroderma)

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Sjögren's syndrome in progressive systemic sclerosis (scleroderma).

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Clinical and serologic study of Sjögren's syndrome in patients with progressive systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Electromyographic findings in various forms of progressive systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Autoantibody to RNA polymerase I in scleroderma sera

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Antinuclear antibody with distinct specificity for polymyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Kinetochore structure, duplication, and distribution in mammalian cells: analysis by human autoantibodies from scleroderma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Human anticentromere antibodies: distribution, characterization of antigens, and effect on microtubule organization

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Three human chromosomal autoantigens are recognized by sera from patients with anti-centromere antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Anticentromere and anticentriole antibodies in the scleroderma spectrum

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Centromere antibodies and antibodies against Scl 70 nucleoprotein in progressive systemic scleroderma. Diagnostic and prognostic significance

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

The CREST syndrome: a distinct serologic entity with anticentromere antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Anticentromere antibody: an immunological marker of a subset of systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis-scleroderma overlap

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Antibodies to collagen in scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Endothelial injury in scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Cytotoxicity of sera from patients with scleroderma. Effects on human endothelial cells and fibroblasts in culture.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Cytotoxic activity of sera from scleroderma and other connective tissue diseases. Lack of cellular and disease specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Polypeptide transforming growth factors isolated from bovine sources and used for wound healing in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Suppressor cell function and t lymphocyte subpopulations in peripheral blood of patients with progressive systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Autologous and allogeneic mixed lymphocyte reactions in progressive systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Lymphokine stimulation of collagen accumulation

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Soluble mediators from mononuclear cells increase the synthesis of glycosaminoglycan by dermal fibroblast cultures derived from normal subjects and progressive systemic sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Inhibition of collagen synthesis by mononuclear cell supernates

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Lymphokine/monokine inhibition of fibroblast proliferation and collagen production: role in progressive systemic sclerosis (PSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Synthesis of types I, III and AB2 collagen by chick tendon fibroblasts in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Human Skin Fibroblasts Derived from Papillary and Reticular Dermis: Differences in Growth Potential in Vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Variability in Collagen and Fibronectin Synthesis by Scleroderma Fibroblasts in Primary Culture

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Collagen synthesis by scleroderma fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Fibroblast selection in scleroderma. An alternative model of fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

A fibroblast mitogen present in scleroderma but not control sera: inhibition by proteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Replication and phenotypic expression of control and scleroderma human fibroblasts: responses to growth factors

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Glycosaminoglycans in scleroderma and scleredema

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Immunohistochemical demonstration of proteoglycans in the skin of patients with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Collagen in the cellular and fibrotic stages of scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Scleroderma: increased biosynthesis of triple-helical type I and type III procollagens associated with unaltered expression of collagenase by skin fibroblasts in culture

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Protocollagen Proline Hydroxylase Activity in the Skin of Normal Human Subjects and of Patients with Scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Type III collagen aminopropeptide levels in serum of patients with progressive systemic scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Collagen synthesis in scleroderma: selection of fibroblast populations during subcultures.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Increased procollagen mRNA levels in scleroderma skin fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Activation of type I collagen genes in cultured scleroderma fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Aminoterminal extension peptides from type I procollagen normalize excessive collagen synthesis of scleroderma fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Collagen synthesis regulation by the aminopropeptide of procollagen I in normal and scleroderma fibroblasts.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

10 Posttranslational enzymes in the biosynthesis of collagen: Intracellular enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Collagen biosynthesis in systemic scleroderma: regulation of posttranslational modifications and synthesis of procollagen in cultured fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Collagen fibrillogenesis: a mechanism of structural biology

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

INTERMITTENT EPOPROSTENOL (PROSTACYCLIN) INFUSION IN PATIENTS WITH RAYNAUD'S SYNDROME

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

The effect of intermittent low molecular dextran infusions upon the digital circulation in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Nifedipine and Raynaud's phenomenon.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Controlled Double-Blind Trial of Nifedipine in the Treatment of Raynaud's Phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Reversal of Vascular and Renal Crises of Scleroderma by Oral Angiotensin-Converting-Enzyme Blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Treatment of generalized scleroderma with inhibitors of collagen synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

The 2-oxoglutarate binding site of prolyl 4-hydroxylase. Identification of distinct subsites and evidence for 2-oxoglutarate decarboxylation in a ligand reaction at the enzyme-bound ferrous ion

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

Regulation of protein synthesis: translational control by procollagen-derived fragments

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2888%2970070-5

7 January 2021

10.1016/S0190-9622(88)70070-5

Identifiers

DOI

1 reference

13 September 2017

1 reference

PubMed ID

3280619